US Pre-Market SEC Filings Roundup — September 03, 2026
This overnight filing cycle is dominated by a surge in SPAC activity, with four major business combination announcements (PlusAI, Remix Therapeutics, Ursa Major, Elroy Air) signaling a potential resurgence in the de-SPAC market. A significant capital allocation theme emerges from large-scale share repurchase programs at Toyota (JPY 1 trillion) and ORIX (¥250 billion), indicating strong corporate confidence in undervaluation. The biotech sector presents a stark contrast, with Passage BIO's cash-burning pre-revenue status and a major licensing deal between HUTCHMED and GSK, highlighting the sector's binary risk/reward profile. Insider selling is concentrated in the technology sector, with multiple executives at Rackspace Technology and RxSight reducing their holdings, which warrants caution. A notable related-party acquisition by Scienjoy Holding and a highly dilutive financing structure for Ribbon Acquisition Corp. present complex risk/reward scenarios for investors.